Broader NGS Use in Oncology Hinges on Payers, Access, and Education

Meir Rinde
Published: Friday, Aug 16, 2019
Dr. David Spigel

David Spigel, MD
David R. Spigel, MD, chief scientific officer and director of lung cancer research at Sarah Cannon Research Institute in Nashville, Tennessee, is among a growing number of believers in the power of next-generation sequencing (NGS) of tumor tissue. They say that using up-front, broadpanel genomic tests that include hundreds of genes can save money and, in some cases, improve outcomes compared with other diagnostic approaches, especially in lung cancer but also increasingly in breast, colorectal, skin, and other cancers.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x